Vomaris Innovations, Inc. is a regenerative medical device company located in Chandler, Arizona, that specializes in microcurrent field generating technologies for the wound care market. Its wound care device which underwent recent testing is called Procellera®. The device consists of a discrete matrix of silver and zinc dots placed on a pliable polyester substrate. By adding saline, which is an ionic fluid, to the Procellera® device before laying it on a wound, the physician is creating a sustained voltage of approximately 0.8V between the Ag and Zn dots. According to Vomaris officials, such a field is comparable to the transcutaneous voltage potential developed in injured skin.
New Study Shows 45% Faster Wound Healing

Researchers tested the product on patients in two nursing homes. The test involved 38 patients, both male and female, of ages ranging 18 to 99. Twenty of the patients were in the Standard of Care (SOC) group, who researchers gave the standard wound treatment care and 18 were in the treated group.
Patients treated with the silver and zinc Procellera® covered with moist double-layered saline soaked gauze were given one application per week.
At the end of the study researchers found that the wounds on the SOC patients, who received the standard of care, closed in an average of 36.25 days. The wounds of those treated with the Procellera® material closed in 19.75 days. According to the researchers, the Procellera® (zinc and silver) treated wounds not only showed more robust healing but they closed 45.4% faster.
“It’s always a win for a company when its technology can set a new standard, ” said Michael Nagel, Vomaris president and CEO. Jimmy Chow, M.D., a hip and knee specialist at Hedley Orthopaedic Institute, said, “As a joint replacement surgeon, infection control and wound healing are top priorities. Procellera® is a cost-effective solution that is also easier on my hospital and clinical staff. My wounds look great.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.